Rapport Therapeutics, a clinical-stage biotech company focused on neurological and psychiatric disorders, announced its management will participate in two major healthcare investor conferences in June 2026: the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. The company will present updates on its precision medicine pipeline, including its lead drug candidate RAP-219 for epilepsy and bipolar mania. These presentations offer investors insight into the company’s progress and future plans, highlighting promising clinical data such as sustained seizure reduction in phase 2a trials. Investors can access live and archived webcasts on Rapport’s website.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
DMG Blockchain Solutions announced two strategic investments: one in MeetAmi Innovations, a Canadian fintech offering digital asset wealth management platforms, and another in Atomic47 Labs, an AI company focused on secure, sovereign AI infrastructur...
Gnosis (GNO) surged 13% in 24 hours, closing in on overtaking BONK by market capitalization to reach the 100th largest token spot. GNO's market cap stands at $303.88 million versus BONK's $330.07 million, requiring a price rise to about $125.48 for t...
Broadridge's Tokenization Pulse Survey shows 84% of firms view tokenization as strategically important, with 68% expecting it to reshape markets within 3-5 years. Most firms plan to integrate tokenization into existing infrastructure rather than buil...
